JANX Janux Therapeutics, Inc.
Janux Therapeutics, Inc. (JANX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 67% planned / 33% discretionary
Largest single sale: $501.0K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr | Sell | 4,059 | $14.03 | $56.9K | 75,941 −5.1% of holding | |
| Dobek Maria | Vice President, Accounting | Sell | 2,038 | $14.17 | $28.9K | 32,270 −5.9% of holding | |
| Campbell David Alan | President and CEO | Sell | 8,072 | $13.73 | $110.8K | 284,982 −2.8% of holding | |
| McIver Zachariah | Chief Medical Officer | Sell | 2,714 | $13.73 | $37.3K | 23,286 −10.4% of holding | |
| DiRaimondo Thomas | Chief Scientific Officer | Sell | 2,505 | $13.73 | $34.4K | 124,425 −2% of holding | |
| Winter Charles M. | Chief Technical Officer | Sell | 2,401 | $13.73 | $33.0K | 77,721 −3% of holding | |
| Meyer Andrew Hollman | Chief Business Officer | Sell | 1,879 | $13.73 | $25.8K | 83,095 −2.2% of holding | |
| Dobek Maria | Vice President, Accounting | Sell | 1,462 | $13.73 | $20.1K | 15,373 −8.7% of holding | |
| Meyer Andrew Hollman 2 fills | Chief Business Officer | Sell 10b5-1 | 3,333 | $32.98 | $109.9K | 85,607 −3.7% of holding | |
| Meyer Andrew Hollman | Chief Business Officer | Sell 10b5-1 | 3,333 | $30.00 | $100.0K | 84,974 −3.8% of holding | |
| Meyer Andrew Hollman | Chief Business Officer | Sell 10b5-1 | 16,665 | $30.06 | $501.0K | 82,139 −16.9% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.